TSHA Stock Analysis: Buy, Sell, or Hold?
TSHA - Taysha Gene Therapies, Inc. Common Stock
$6.99
0.13 (1.82%)
▲
5d:
+19.4%
30d:
+27.23%
90d:
+69.13%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Smart Money Accumulation
None View Scanner →
Strength: 5.5/10
Get Alerted When TSHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: TSHA is 13.4% above its trading range ($6.16). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: TSHA is 13.4% above its trading range ($6.16). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: TSHA is currently trading at $6.99, which is considered extended relative to its 30-day fair value range of $5.39 to $6.16.
Technical Outlook: Technically, TSHA is in a strong uptrend. The price is approaching resistance at $7.05. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TSHA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.23 (+78.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TSHA is in a strong uptrend. The price is approaching resistance at $7.05. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TSHA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $12.23 (+78.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.39 -
$6.16
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BEARISH: Price significantly overextended (+13.4% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 78.3% below Wall St target ($12.23)
Trading Range Analysis
30-Day Trading Range
$5.39 -
$6.16
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.26
Resistance Level
$7.06
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-15.50
Wall Street Target
$12.23
(+78.3%)
Revenue Growth (YoY)
171.3%
Share & Embed Analysis
Last updated: June 24, 2026 12:42 PM ET
Data refreshes hourly during market hours. Next update: 1:42 PM
Data refreshes hourly during market hours. Next update: 1:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TSHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Sukumar Nagendran
SELL
200000 shares
2026-04-10
Kamran Alam
SELL
1655 shares
2026-02-04
Kamran Alam
SELL
23849 shares
2026-01-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 57 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
12 analysts |
$139 | 65 BUY |
